Pharmacokinetics of CPX 351; A nano scale liposomal fixed molar ratio formulation of cytarabine: Daunorubicin, In patients with advanced leukemia

Leukemia Research

Volumn 36, Issue 10, 2012, Pages 1283-1289

  Feldman, E J ^a   Kolitz, J E ^b   Trang, J M ^c   Liboiron, B D ^d   Swenson, C E ^e   Chiarella, M T ^e   Mayer, L D ^d,e   Louie, A C ^e   Lancet, J E ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b North Shore Long Island Center for Advanced Medicine   (United States)

^c PK/PD International Inc   (United States)

^d Celator Pharmaceuticals Corp   (Canada)

^e Celator Pharmaceuticals Inc   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; CPX 351; Cytarabine; Daunorubicin; Liposome; Pharmacokinetics; Phase 1

Indexed keywords

ANTILEUKEMIC AGENT; CPX 351; CYTARABINE PLUS DAUNORUBICIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CANCER MORTALITY; CARDIOMYOPATHY; CLINICAL ARTICLE; COHORT ANALYSIS; COUGHING; CYTOPENIA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERTENSIVE CRISIS; HYPOPLASIA; INFECTION; LEUKEMIA; LIPOSOMAL DELIVERY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NANOENCAPSULATION; NAUSEA; NEUTROPENIA; PETECHIA; PHARMACODYNAMICS; PRIORITY JOURNAL; SEPSIS; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; LEUKEMIA; LIPOSOMES; MALE; MIDDLE AGED; NANOTECHNOLOGY; PROGNOSIS;

EID: 84865154500     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.006     Document Type: Article

References (26)

1. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
2. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
3. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
4. Schiffer C.A., Stone R.M. Acute myeloid leukemia in adults. Cancer Medicine 7 2006, 1739-1760. BC Decker, Inc., Hamilton, ON. D.W. Kufe, R.C. Bast, W.N. Hait, W.K. Hong, R.E. Pollock, R.R. Weichselbaum, J.F. Holland, E. Frei (Eds.).
5. Bishop J.F., Matthews J.P., Young G.A., Szer J., Gillett A., Joshua D., et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
6. Lowenberg B., Ossenkoppele G.J., van Putten W., Schouten H.C., Graux C., Ferrant A., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
7. Goldie J.H., Coldman A.J. Application of theoretical models to chemotherapy protocol design. Cancer Treat Rep 1986, 70:127-131.
8. Frei E., Eder J.P. Principles of dose, schedule and combination therapy. Cancer Medicine 7 2006, 590-599. BC Decker, Inc., Hamilton, ON. D.W. Kufe, R.C. Bast, W.N. Hait, W.K. Hong, R.E. Pollock, R.R. Weichselbaum, J.F. Holland, R. Frei (Eds.).
9. Chou T.C., Theoretical basis experimental design, and computerized simulation of synergsim and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
10. Greco W.R., Bravo G., Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995, 47:331-385.
11. Harasym T.O., Tardi P.G., Johnstone S.A., Mayer L.D., Bally M.B., Janoff A.S. Fixed drug ratio liposome formulations of combination cancer therapeutics. Liposome Technology (3rd ed) Volume III: Interactions of Liposomes with Biological Milieu 2007, 25-46. Informa Healthcare USA Inc., New York. G. Gregoriadis (Ed.).
12. Mayer L.D., Janoff A.S. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 2007, 7:216-223.
13. Tardi P.G., Johnstone S.A., Harasym N.L., Xie S., Harasym T.O., Zisman N., et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009, 33:129-139.
14. Lim W.S., Tardi P.G., Dos Santos N., Xie X., Fan M., Liboiron B.D., et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 2010, 34:1214-1223.
15. Harasym T.O., Liboiron B.D., Mayer L.D. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Multi-drug Resistance in Cancer 2010, Humana Press, New York. J. Zhou (Ed.).
16. Mayer L.D., Harasym T.O., Tardi P.G., Harasym N.L., Shew C.R., Johnstone S.A., et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006, 5:1854-1863.
17. Feldman E.J., Lancet J.E., Kolitz J.E., Ritchie E.K., Roboz G.J., List A.F., et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011, 29:979-985.
18. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, New York. 2nd ed.
19. Robert J., Rigal-Huguet F., Hurteloup P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematol Oncol 1992, 10:111-116.
20. Fleming R.A., Capizzi R.L., Rosner G.L., Oliver L.K., Smith S.J., Schiffer C.A., et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol 1995, 36:425-430.
21. Ciofani T., Harasym T., Juan M.C.Y., Mayer L., Cabral-Lilly D., Xie S. Determination of Total and Encapsulated Drug Pharmacokinetics of CPX-351, A Nanoscale Liposomal Fixed Molar Ratio of Cytarabine-Daunorubicin (Cyt:Daun) 2011, American Association of Cancer Research 102nd Annual Meeting, Orlando, FL.
22. Lancet J.E., Cortes J.E., Hogge D.E., Tallman M., Kovacsovics T., Damon L.E., et al. Phase 2B randomized study of CPX-351 vs. cytarabine (CYT) + daunorubicin (DNR) (7+3 regimen) in newly diagnosed AML patients aged 60-75. Blood 2010, 116:665.
23. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54:987-992.
24. Mross K., Niemann B., Massing U., Drevs J., Unger C., Bhamra R., et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open label, single-dose study. Cancer Chemother Pharmacol 2004, 54:514-524.
25. Kim H.P., Gerhard B., Harasym T.O., Mayer L.D., Hogge D.E. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol 2011, 39:741-750.
26. Kolitz J.E., Cortes J., Hart K., Louie A. CPX-351: A randomized phase 2b study in ≤65 younger first relapse AML patients. J Clin Oncol 2010, 28:15s.